Preventing CMV after lung transplant: letermovir vs. valganciclovir
Treatments studied
Part of Infections clinical trials.
This study compares a new antiviral drug (letermovir) to a standard one (valganciclovir) for preventing CMV infection after lung transplant. It is for people who are at high risk because the donor had CMV but the recipient did not.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You received a lung transplant from a donor who had CMV, but you did not have CMV before the transplant (D+/R-).
- You have a negative CMV test within 96 hours before starting letermovir.
- You are not infected with HIV.
- You did not receive a transplant of multiple organs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two antiviral medications to prevent CMV (a common virus that can cause problems after kidney transplant) in people who had the virus before their transplant. The goal is to see which medicine works better and is safer for preventing CMV disease.
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
This trial tests if an oral medication called letermovir can prevent CMV infection in heart or lung transplant recipients who are at risk for CMV. It may offer a convenient option to protect against this virus after transplant.
This study tests if doctors can safely stop the anti-CMV drug letermovir earlier in stem cell transplant patients who have recovered their immune system. It focuses on patients who are at high risk for CMV but currently have no active infection.
This trial compares two antiviral drugs, valganciclovir and letermovir, to see which works better at preventing CMV infection after a heart transplant. If you've had a heart transplant and haven't started preventive treatment yet, this study may be for you.
This study looks at how to prevent and monitor a virus called CMV after a lung transplant. It is for adults who are not carrying CMV themselves, but who receive lungs from donors who are CMV-positive, and it may help tailor safer follow-up care after transplant.
Hear when a new Infections, Cytomegalovirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.